Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

atment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that new distribution agreements or other commercialization efforts will effectively accelerate InnerCool's patient temperature modulation business, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, that necessary regulatory approvals will be obtained. Actual results may also
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
(Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
(Date:3/25/2015)... 2015 Data from Evidence of ... Action in Neuromuscular Diseases , South San ... (Nasdaq: CYTK) announced the publication of a manuscript ... tirasemtiv in the journal Neurotherapeutics. This publication ... Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies ... lethal strains of E. Coli preceded the current E. Coli ... in laboratories in Germany and elsewhere since 1995, and genome ... subsequences of the genome of an infectious agent that have ...
... June 20, 2011 Genetic Technologies Limited (ASX: GTG; ... division, Phenogen Sciences Inc., has launched the new BREVAGen™ ... Phenogen Sciences will target its promotion campaign ...  The company has deployed its sales force to service ...
... , Kuros Biosurgery AG, a ... and bioactive-biomaterial,combination products for trauma, wound and spinal ... by the European Patent Office. This now allowed ... portfolio of applications,and patents designed to protect Kuros’ ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4Kuros Announces Allowance of European Patent for Synthetic Biomaterials 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 3
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... Beta Systems today announced ... management (IAM) solution for a fixed price and ... new IAM package, customers benefit from the 30 ... IAM implementations across different industries. The new fixed-price ... any necessary services and consulting. It spans the ...
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... may help prevent potentially dangerous bacteria like Staphylococcus ... animals, scientists heard today (Monday 8 September 2008) ... being held this week at Trinity College, Dublin. ... protect them against antibiotics and the body,s natural ...
... Researchers in Switzerland have developed a new ... in microfluidic systems, these "Pyrex"-like nanoparticles are ... and harsh chemical environments than currently used ... Their introduction could extend the range of ...
... INCF Congress of Neuroinformatics will convene September 7-9 ... The emerging neuroinformatics field combines neuroscience and informatics ... understanding the structure and function of the brain. ... disorders and diseases. With a broad international outreach, ...
Cached Biology News:Milk may help bacteria survive against low levels of antibiotics 2INCF organizes the first congress dedicated to the emerging field of neuroinformatics 2